Sign inJoin waitlistJoin the waitlist

Sami Ibrahimi

Fellowship Director · University of Oklahoma College of Medicine

Credentials: · · · · · ·

History

University of Oklahoma College of Medicine Fellowship
Present
University of Oklahoma College of Medicine · University of Oklahoma Health Sciences Center
Present

Hematology/Oncology University of Oklahoma Health Sciences Center
2015–2018
Internal Medicine
Tufts University School of Medicine
2012–2015
OU Health Sciences Center
University of Jordan Faculty of Medicine
2006–2010

Research

Paradoxical effects of obesity on T cell function during tumor progression and PD-1 checkpoint blockade
Nature Medicine · 2019 · 752 citations
Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or…
The Lancet · 2022 · 698 citations
Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study
Blood · 2023 · 369 citations

Sarbajit Mukherjee
12 papers · 11 as a fellow
JA
Jeremy Abramson
7 papers
Jon Arnason
7 papers
Manali Kamdar
7 papers
Patrick Johnston
7 papers
SS
Scott Solomon
7 papers
Francisco Hernandez-Ilizaliturri
6 papers
Matthew Lunning
6 papers
Veronika Bachanova
6 papers
Adam Asch
5 papers
Mohamad Cherry
5 papers
Raid Aljumaily
5 papers

Clinical trials

Testing the Safety of Anti-Cancer Drug, CX-5461 (Pidnarulex), in Treating Lymphoma With Specific Changes in the MYC Gene
Principal investigator · Recruiting · Phase 1, Phase 2
National Cancer Institute (NCI)
2026–2030
Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Site PI · Recruiting · Phase 1
National Cancer Institute (NCI)
2024–2027
Comparing the Effectiveness of the Immunotherapy Agents Rituximab or Mosunetuzumab in Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma, NORM Trial
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2024–2026
Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
Site PI · Recruiting · Phase 2
SWOG Cancer Research Network
2023–2030